Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing outcomes in depression: focus on antidepressant compliance.

M B Keller1, R M A Hirschfeld, K Demyttenaere

  • 1Department of Psychiatry, Brown University Medical School, RI 02906, USA. barbararyan@brown.edu

International Clinical Psychopharmacology
|November 1, 2002
PubMed
Summary

Major depressive disorder (MDD) is a recurring illness often undertreated. Improving patient and physician education and using better-tolerated antidepressants can enhance medication compliance and treatment outcomes for MDD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Measurement of doctor wellbeing prior to the Covid pandemic: a methodological systematic review.

Occupational medicine (Oxford, England)·2025
Same author

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

European archives of psychiatry and clinical neuroscience·2024
Same author

Effects of mindfulness-based interventions on symptoms and interoception in trauma-related disorders and exposure to traumatic events: Systematic review and meta-analysis.

Psychiatry research·2024
Same author

[Interstitial pneumonia and venlafaxine use].

Tijdschrift voor psychiatrie·2023
Same author

[A suspected case of factitious disorder].

Tijdschrift voor psychiatrie·2021

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is a chronic, recurrent illness with significant morbidity and mortality.
  • MDD is often unrecognized and undertreated, despite its high prevalence.
  • Recurrent depressive episodes tend to be longer, more severe, and less responsive to treatment.

Purpose of the Study:

  • To highlight the critical role of antidepressant medication compliance in managing recurrent depression.
  • To identify key factors influencing patient compliance with antidepressant treatment.
  • To discuss the potential of newer antidepressant classes in improving compliance and outcomes.

Main Methods:

  • Literature review focusing on patient compliance in major depressive disorder.

Related Experiment Videos

  • Analysis of factors affecting antidepressant adherence, including psychological, pharmacological, and educational aspects.
  • Comparison of tolerability and potential compliance benefits of newer antidepressants versus older agents.

    • Main Results:

    • Poor compliance with antidepressant medication is a significant barrier in treating recurrent MDD.
    • Patient education, physician awareness, psychological factors, speed of onset, and medication tolerability all influence compliance.
    • Newer antidepressants (SSRIs, SNRIs, SNRIs) demonstrate better tolerability than tricyclic antidepressants, potentially improving compliance.

    Conclusions:

    • Enhancing patient and physician education is crucial for improving antidepressant compliance.
    • Medication tolerability is a key factor influencing adherence in MDD treatment.
    • The improved tolerability profile of newer antidepressants may lead to better compliance and treatment outcomes in managing major depressive disorder.